Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
35.32
-1.68 (-4.54%)
At close: Aug 28, 2026, 4:00 PM EDT
35.40
+0.08 (0.23%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Pharvaris Employees
Pharvaris had 148 employees as of June 30, 2026. The number of employees increased by 34 or 29.82% compared to the same quarter last year.
Employees
148
Change
34
Growth
29.82%
Revenue / Employee
n/a
Profits / Employee
-$1,319,403
Market Cap
2.48B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 148 | 34 | 29.82% |
| Mar 31, 2026 | 134 | 15 | 12.61% |
| Dec 31, 2025 | 129 | 21 | 19.44% |
| Sep 30, 2025 | 118 | 26 | 28.26% |
| Jun 30, 2025 | 114 | 31 | 37.35% |
| Mar 31, 2025 | 119 | 36 | 43.37% |
| Dec 31, 2024 | 108 | 26 | 31.71% |
| Sep 30, 2024 | 92 | 22 | 31.43% |
| Jun 30, 2024 | 83 | 15 | 22.06% |
| Mar 31, 2024 | 83 | 17 | 25.76% |
| Dec 31, 2023 | 82 | 17 | 26.15% |
| Sep 30, 2023 | 70 | 14 | 25.00% |
| Jun 30, 2023 | 68 | 21 | 44.68% |
| Mar 31, 2023 | 66 | 25 | 60.98% |
| Dec 31, 2022 | 65 | 31 | 91.18% |
| Sep 30, 2022 | 56 | 39 | 229.41% |
| Jun 30, 2022 | 47 | 30 | 176.47% |
| Mar 31, 2022 | 41 | 27 | 192.86% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Vera Therapeutics | 361 |
| Nuvation Bio | 305 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| Kodiak Sciences | 141 |
| Rapport Therapeutics | 84 |
PHVS News
- 13 days ago - Pharvaris reports Q2 EPS (EUR 0.70) vs. (EUR 0.83) last year - TheFly
- 13 days ago - Pharvaris price target raised to $75 from $74 at Citizens - TheFly
- 13 days ago - Pharvaris price target raised to $38 from $35 at BofA - TheFly
- 13 days ago - Pharvaris price target raised to $40 from $39 at Guggenheim - TheFly
- 17 days ago - Pharvaris Earnings release: Q2 2026 - Filings
- 17 days ago - Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology - GlobeNewsWire
- 4 weeks ago - Pharvaris price target raised to $35 from $33 at BofA - TheFly